Prognostic impact of MMP‐2 and MMP‐9 expression in pathologic stage IA non‐small cell lung cancer

The purpose of the present study was to assess the value of matrix metalloproteinase (MMP)‐2 and MMP‐9 expression and other potential prognostic factors in predicting the clinical outcome of patients after definitive surgery for pathologic stage IA non‐small cell lung cancer (NSCLC).

[1]  H. Kato,et al.  Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer , 2001, British Journal of Cancer.

[2]  M. Sonobe,et al.  Expression of tissue inhibitor of metalloproteinase‐3 (TIMP‐3) and its prognostic significance in resected non‐small cell lung cancer , 2007, Journal of surgical oncology.

[3]  N. Martini.  Mediastinal lymph node dissection for lung cancer. The Memorial experience. , 1995, Chest surgery clinics of North America.

[4]  K. Ishikawa,et al.  Smoking history before surgery and prognosis in patients with stage IA non-small-cell lung cancer--a multicenter study. , 2005, Lung cancer.

[5]  T. Naruke,et al.  Lymph node mapping and curability at various levels of metastasis in resected lung cancer. , 1978, The Journal of thoracic and cardiovascular surgery.

[6]  Ivan Stamenkovic,et al.  Extracellular matrix remodelling: the role of matrix metalloproteinases , 2003, The Journal of pathology.

[7]  W. Mutschler,et al.  Prognostic impact of matrix metalloproteinase‐9 in operable non‐small cell lung cancer , 2003, International journal of cancer.

[8]  L V Rubinstein,et al.  Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. , 1995, The Annals of thoracic surgery.

[9]  P. Granone,et al.  Factors predicting poor survival after resection of stage IA non-small cell lung cancer. , 2008, The Journal of thoracic and cardiovascular surgery.

[10]  A. Gajra,et al.  Impact of tumor size on survival in stage IA non-small cell lung cancer: a case for subdividing stage IA disease. , 2003, Lung cancer.

[11]  J. Westermarck,et al.  Regulation of matrix metalloproteinase expression in tumor invasion , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  H. Wada,et al.  Matrix Metalloproteinase-2 Status in Stromal Fibroblasts, Not in Tumor Cells, Is a Significant Prognostic Factor in Non–Small-Cell Lung Cancer , 2004, Clinical Cancer Research.

[13]  R. Menon,et al.  Screening of Novel Matrix Metalloproteinases (MMPs) in Human Fetal Membranes , 2002, Journal of Assisted Reproduction and Genetics.

[14]  R. Khokha,et al.  Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development , 2003, British Journal of Cancer.

[15]  N. Yamasaki,et al.  Stage IA non-small cell lung cancer: vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy. , 2007, Lung cancer.

[16]  C. Angeletti,et al.  Blood vessel invasion by tumor cells predicts recurrence in completely resected T1 N0 M0 non-small-cell lung cancer. , 1993, The Journal of thoracic and cardiovascular surgery.

[17]  Ying Sun,et al.  Expression of KISS1 and MMP-9 in non-small cell lung cancer and their relations to metastasis and survival. , 2010, Anticancer research.

[18]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[19]  G. Blumenstock,et al.  Prognostic value and therapeutic consequences of vascular invasion in non-small cell lung carcinoma. , 2009, Lung cancer.

[20]  I Yoshino,et al.  Prognostic factors obtained by a pathologic examination in completely resected non-small-cell lung cancer. An analysis in each pathologic stage. , 1995, The Journal of thoracic and cardiovascular surgery.

[21]  D. Libby,et al.  Tumor size predicts survival within stage IA non-small cell lung cancer. , 2003, Chest.

[22]  Y. Maehara,et al.  Prognostic significance of intratumoral blood vessel invasion in pathologic stage IA non-small cell lung cancer. , 2010, The Annals of thoracic surgery.

[23]  R. Kerbel.  Tumor angiogenesis: past, present and the near future. , 2000, Carcinogenesis.

[24]  K. O'Byrne,et al.  Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  W. Travis,et al.  Expression of matrix metalloproteinases in invasive pulmonary adenocarcinoma with bronchioloalveolar component and atypical adenomatous hyperplasia. , 2001, The American journal of pathology.

[26]  M. Tsao,et al.  Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation , 2006, Journal of Clinical Pathology.

[27]  K. Sugita,et al.  Antitumor Efficacy of Hypothemycin, A New Ras‐signaling Inhibitor , 1999, Japanese journal of cancer research : Gann.

[28]  Y. Sakao,et al.  Carcinoembryonic antigen as a predictive factor for postoperative tumor relapse in early-stage lung adenocarcinoma. , 2004, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[29]  Hiroshi Sato,et al.  Expression of membrane-type-1-matrix metalloproteinase and metalloproteinase-2 in nonsmall cell lung carcinomas. , 2002, Lung cancer.

[30]  K. O'Byrne,et al.  A biological staging model for operable non-small cell lung cancer , 2001, Thorax.

[31]  R. Welsh,et al.  Prognostic factors in T1 NO MO adenocarcinomas and bronchioloalveolar carcinomas of the lung. , 1999, American journal of clinical pathology.

[32]  Carlos López-Otín,et al.  Strategies for MMP inhibition in cancer: innovations for the post-trial era , 2002, Nature Reviews Cancer.

[33]  Y. Otani,et al.  Late-onset chylothorax after pulmonary resection and systematic mediastinal lymph node dissection for lung cancer. , 2005, The Japanese Journal of Thoracic and Cardiovascular Surgery.

[34]  S. Kuo,et al.  Expression spectra of matrix metalloproteinases in metastatic non-small cell lung cancer. , 2004, Oncology reports.

[35]  N. Ridgway,et al.  Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. , 2011, Journal of thoracic disease.

[36]  B. Fox,et al.  Active-specific immunotherapy for non-small cell lung cancer. , 2011, Journal of thoracic disease.

[37]  W. Stetler-Stevenson,et al.  The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. , 1994, The European respiratory journal.

[38]  U. Morandi,et al.  The prognostic impact of tumor size in resected stage I non-small cell lung cancer: evidence for a two thresholds tumor diameters classification. , 2006, Lung cancer.

[39]  C. Bucana,et al.  Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  W. Mutschler,et al.  Overexpression of Matrix Metalloproteinase 2 Predicts Unfavorable Outcome in Early-Stage Non-Small Cell Lung Cancer 1 , 2000 .

[41]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[42]  Jianxing He,et al.  The role of gene expression profiling in early-stage non-small cell lung cancer. , 2010, Journal of thoracic disease.

[43]  E. Miyaoka,et al.  Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. , 2005, Lung cancer.